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Proteomic techniquesAbstract Colon cancer is the most common type of cancer and major cause of death worldwide.
The detection of colon cancer is difﬁcult in early stages. However, the secretory proteins have been
used as ideal biomarker for the detection of colon cancer progress in cancer patients. Serum/tissue
protein expression could help general practitioners to identify colon cancer at earlier stages. By this
way, we use the biomarkers to evaluate the anticancer drugs and their response to therapy in cancer
models. Recently, the biomarker discovery is important in cancer biology and disease management.
Also, many measurable speciﬁc molecular components have been studied in colon cancer therapeu-
tics. The biomolecules are mainly DNA, RNA, metabolites, enzymes, mRNA, aptamers and pro-
teins. Thus, in this review we demonstrate the important protein biomarker in colon cancer
development and molecular identiﬁcation of protein biomarker discovery.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Colon cancer is a complex process involving multiple changes
in genomic and proteomic levels. Colon cancer is a gradual
progression from benign polyps/cysts and development
late stage and metastasis (Reimers et al., 2013). It is primarymetastasis to the liver and other distinct organs such as GIT
and pancreas, etc. The serum protein expression is often signif-
icantly raised in patient’s samples which are affected by colon
and other cancers (Kievit et al., 1990; Ward et al., 2006).
Despite the numerous clinical studies which demonstrate that
there is importance for monitoring cell adhesion proteins that
can be used to control further invasion and metastasis
(Polanski et al., 2006). Biomolecules such as protein, DNA,
miRNA and enzymes are the most accessible biological mate-
rials and detection of biomarkers in patients with chronic dis-
eases could be of great clinical relevance, because malignant
tumor cells release several proteins and extracellular ﬂuids
(ECF) into the blood stream and tissues. Some literature state
that tumors released numerous proteins into the blood streams (2014),
Figure 2 Flowchart for protein biomarker analysis using
2 P. Kuppusamy et al.when compared to healthy human beings (Bu¨nger et al., 2011;
Fijneman et al., 2012).
Still, proteome study is particularly challenging due to its
complex structure and function. Clinical specimens such as
blood, stool and tissues contain several hundreds of secretory
proteins. The proteins are essential for normal cell mechanisms
and signaling, they secreted from different cellular organs
(Maurya et al., 2007). Some of the proteins are specially
secreted under pathological conditions, it’s mainly due to the
alternative mRNA synthesis and other chromosomal genetic
variations including cancer, diabetes and Alzheimer disease
(Deschoolmeester et al., 2010). Therefore, the vast dynamic
range of proteins has been increased to study under cancer’s
pathological conditions and it is one of the novel biomarkers
to ﬁnd out the disease status. These kinds of proteins are
released by tumor cells and will be found in blood and tissues
(Rangiah et al., 2009). The receptor proteins could be identi-
ﬁed by advanced analytical techniques such as mass spectrom-
etry (MS) and MALDI-TOF, etc. Those methods have
reduced the high amount of sample usage, rather it uses thresh-
old or nanogram levels (Tanaka et al., 2010). Proteins are
widely important for cellular mechanisms such as cell growth,
cell signaling, protein metabolic process and cell motility
(Karley et al., 2011). Ultimately, the proteomic studies identi-
ﬁed the number of protein biomarkers. These protein biomark-
ers are benchmarked for colon cancer identiﬁcation and
therapeutics. For instance, the over-expressed glycoprotein is
responsible for tumor growth and spread into distinct parts.
The secreted protein is multifunctional and is implicated in
malignancies including the stomach, lung, prostate, liver and
colon (Ward et al., 2006). Also, these up regulated proteins
stimulated tumorigenesis, including cell adhesion and invasion
and migration of tumor cells.
Biomarker discovery has been developed in different steps.
Firstly, the discovered biomarkers are subjected to veriﬁcation
and followed by development and ﬁnally conﬁrmed in clinical
validation (Bodovitz et al., 2003; Wahs-Oquendo et al., 2012).
These biomarkers can be classiﬁed into different forms such as
genetic biomarker, epigenetic biomarker, protein biomarker,
metabolites’ biomarker and immunological biomarker (Zhai
et al., 2012). Fig. 1 shows the pipeline for protein biomarker
discovery. The biomarkers can be assessed by various tools
such as radiological techniques, high-throughput microarrays,
2DE (two-dimensional gel electrophoresis), western blotting
and mass spectrometry. Also, the potentially important cancer
biomarkers have been used to accurately detect the expression
level of cell adhesion proteins and metabolites through these
techniques (Bhatt et al., 2010). In this investigation, we focused
on different protein biomarker expression in colon cancer and
various proteomic techniques. These secretory proteins are
novel biomarkers to identify colon cancer conditions.Figure 1 Pipeline for protein
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The molecular study of cancer is mainly the study of protein
expression proﬁle and its prognostic information to support
clinical decision making for cancer treatment. Signal mediating
proteins are expressed in the normal biological processes, path-
ogenic conditions and pharmacologic responses of drugs. The
up/down regulation of biological molecules such as proteins,
DNA, abnormal methylation patterns, miRNAs, lipids, glu-
cose and other biological molecules have shown serious path-
ogenic symptoms in the human system (Kocevar et al., 2013).
The protein biomarkers are the mostly used parameters in clin-
ical diagnosis for the detection of over-expressed proteins in
clinical samples (Srivastava et al., 2001). The protein expres-
sion is characterized by different immunoassay techniques
such as ELISA, immunohistochemistry and so on. These tech-
niques have some limitation in clinical practice. For example,
protein detection assays are of high speciﬁcity with antibody
binding, less detection of low abundant proteins and low sen-
sitivity (Kulasingam et al., 2008). However, the proteomic
techniques encompass with nanotechnologies and enhance
the application in identiﬁcation, characterization and stability
of the secretory proteins and their functions. The techniques
are able to detect the complex proteins accurately and quickly.biomarker development.
proteomic tools.
s to detect colon cancer progression. Saudi Journal of Biological Sciences (2014),
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from clinical samples.
1.2. Heat shock proteins
Heat shock proteins (HSP) are a group of proteins, which is
present in all multicellular organisms. HSPs are classiﬁed into
different groups based on their molecular weight such as
hsp10, hsp40, hsp60, hsp70, hsp90 and hsp110 (Mikami
et al., 2009; Vidyasagar et al., 2012). At present, the hsp over
expression in cancer is not yet clear. However, the stress and
temperature of the tumor environment may stimulate the
HSP induction.
For instance, Hsp90 inhibitor chemically called as 17-
(dimethyl amino ethyl amino)-17-demethoxygeldanamycin
(17-DMAG) signiﬁcantly inhibited the phosphorylation of epi-
dermal growth factor receptor in HCT 116 and HT 29 cell
lines. Similarly, it does activate the transcription factor-3,
tumor suppressor and antimetastatic factor on mRNA and
protein synthesis. Therefore, the overall studies show that
17-DMAG prominently induced apoptosis in colon cancer
cells even though the Hsp90 has interesting phenomena in
molecular target for colon cancer therapy in various clinical
studies (Berney et al., 1999). Colon cancer cells secreted certain
signaling components such as EGFR, FAK and c-Met. These
signaling molecules are regulated by 17-DMAG treated colon
cell lines, hence it controlled the cell migration in vitro. Ulti-
mately, blocking Hsp90 leads to enhance the expression of a
transcription factors and antimetastatic mechanism (Moser
et al., 2007).
Heat shock proteins (HSPs) are highly conserved and
involved in various cellular signaling that mediate cell survival
rate in cancers. It has different forms of molecular weight and
presence in different types of cancer. For instance, the inhibi-
tion of HSP 70 expression has to stimulate the intracellular
Ca2+ levels in colon cancer cell lines and led to the release of
intracellular Ca2+ in cell culture environment. Ca2+ induces
the caspase dependent cell death mechanism in colon cancer
cell line. HSP70 inhibits programed cell death in colon cancer
cells and decreased cytosolic calcium level in tissues and stabil-
ization of lysosomes. Also HSP70 upregulates cell survival in
other types of cancer cells such as pancreatic and prostate can-
cer (Dudeja et al., 2009). Morita et al. (2014) found that HSP
40 family member such as DNAJB8 is highly expressed in colo-
rectal cancer. Overexpression of DNAJB8 enhanced the
expression in tumorigenicity indicating that DNAJB8 has a
major role in colorectal cancer prognosis.
1.3. Carcino embryonic antigen (CEA)
CEA is a glycoprotein, the molecular weight 6 200 kDa. CEA
was ﬁrst identiﬁed in 1965 by Gold and Freedman, the antigen
was detected in serum sample of colon cancer patients (Gold
and Freedman, 1965). Elevated CEA levels were observed in
colorectal, breast, lung, or pancreatic cancer patient. CEA is
a member of the immunoglobulin superfamily. It contains
two types of immunoglobulin domains namely an N-terminal
domain such as IgV-like variable domain and IgC2-like con-
stant domain (Duffy et al., 2001). CEA is a well known serum
protein marker which belongs to the immunoglobulin (Ig)
superfamily. It has been acting as a mediator for cell adhesionPlease cite this article in press as: Kuppusamy, P. et al., Proteins are potent biomarker
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(2011) reviewed the current use of 31 active clinical drugs that
target CEA, among which 18 have target action and control
the tumor development in colon cancer patients. But the other
11 drugs are in trials and have been found to less active in tar-
geting CEA and lack tumor response and related toxicities.
These drugs are needed to improve the immunologic activity
against CEA target in colon cancer by using standard vaccine
strategies.
Recent studies showed that the CEA overexpression occurs
in >90% of colorectal cancers and 60% of other types of can-
cer including gastric, lung and pancreatic(Michor et al., 2005).
Moreover, identiﬁcation of the receptor of CEA mediates its
prometastatic activities to other organs and would have great
impact on drug development for cancer treatment (Dwyer
et al., 2011). This CEA-receptor (CEAR) has been identiﬁed
as a homolog of the heterogeneous nuclear ribonucleoprotein
M4 (hnRNP M4). The hnRNP M4 mainly promotes the pre-
mRNA binding mechanisms. In cancer state, hnRNP M4 does
not bind with RNA homopolymers but helps as a nuclear
mRNA-transporter and involves in mRNA splicing. Due to
these biological mechanisms that CEA interacts with a recep-
tor-like molecule (receptor at the membrane of Kupffer cells
and macrophages) to transmit signal transduction activity
and release of various cytokines (Laguinge et al., 2005).
CEA increases the concentration in metastatic CRC to col-
onize in the liver and develop spontaneous pancreatic and lung
metastasis (Li et al., 2010). CEA protein and epitopes have
been identiﬁed from human T lymphocytes (T cells). CEA-
expressing in cancer cells is weakly recognized by the immune
system. Recently, the proteomic studies have introduced sev-
eral new strategies to enhance immune reactions against
CEA. This includes using antibodies directly against CEA,
inserting the CEA gene into recombinant viruses and bacteria
as viral and bacterial vaccines, peptides and DNA or RNA
onto dendritic cells to increase vaccine effectiveness (Ho¨rig
et al., 2000).
1.4. Tissue inhibitor of matrix metalloproteinase 1
Generally, cancer cells are interacting with neighboring cells
through cell receptors and extracellular matrix (ECM). The
ECM and receptor connections with surrounding cells are lar-
gely modiﬁed by the matrix metalloproteinases (MMPs) and
normal protein function. The degrading of ECM mechanism
is mainly involved by MMPs. On the other hand MMP activ-
ities have been regulated by the tissue inhibitors of metallo
proteinases (Bourboulia et al., 2010). TIMPs can inhibit the
function of MMPs with varying conditions and different
MMPs. Human colon cancer enhances the synthesis of
TIMP-1 in cancer model compared to their normal counter-
parts, eventually increasing the growth of cancers. Moreover,
TIMP-1 promotes colon cancer progression and accumulation
of CAFs (Cancer Associated Fibroblasts) in colon cancer.
Also, TIMP-1 has been stimulating the protumor effect in
prostate, colon and other type of cancers (Gong et al., 2013).
Tissue inhibitor metaloprotenase-1 is a glycoprotein present
in various cancerous and noncancerous tissues and bodily ﬂu-
ids. TIMPs have four important classes namely, TIMP-1, -2,
-3, and -4. TIMPs, TIMP-1 and TIMP-2 are mainly involved in
enzyme-inhibitory properties in cancer models (Offenbra et al.,s to detect colon cancer progression. Saudi Journal of Biological Sciences (2014),
4 P. Kuppusamy et al.2008). TIMP-1 has growth-promoting properties and stimu-
lates tumor growth by inhibiting the apoptosis in colon cancer.
TIMP-1 is a novel and speciﬁc protein marker for the identiﬁ-
cation of early-stage colon cancer (CC). In CC patient, blood
plasma sample has signiﬁcantly elevated TIMP-1 levels com-
pared with healthy individuals (Holten-Andersen et al.,
2002). Table 1 explains various important protein biomarkers
discovered from colon cancer clinical samples. Different
molecular marker detection from CRC has been achieved
extensively in clinical use. For instance, variety of enzymes
and other biomolecules have been developed to assess the sta-
tus of CRC, but this approach is also needed to be elaborated
in clinical studies (Ross et al., 2010; Kaler et al., 2014).
Progression of colon cancer is mainly reciprocal interactions
between stroma and cancer cells. Furthermore, the major stro-
mal cell types have been associated with various types of cancer
including colon, liver and breast. Colon cancer is mainly medi-
ated by different signaling and secretary molecules such as cyto-
kines, growth factors, chemokines, proteases, and components
of the extracellular matrix. Some of the potent serum protein
biomarkers identiﬁed are proteinglutamine gamma-glutamyl-
transferase 2 (TGM2), insulin-like growth factor-binding pro-
tein 7 (IGFBP7) and calcyclin binding protein (CacyBP) as
involving in colorectal metastasis (Pan et al., 2009; Katayama
et al., 2006; Zhao et al., 2007; Ghosh et al., 2011). Other tumor-
igenic factors such as cyclooxygenase 2 (COX2), selenoproteins
and inducible nitric oxide synthase (iNOS/NOS2) have often
been involved in colon tumorigenesis (Mcintosh et al., 2008).
These protein biomarkers have an inﬂuence to detect the early
changes in carcinogenesis (Xuezhi et al., 2006).
Evaluating the changes of protein proﬁles associated with
the colorectal tumorigenesis will be potential therapeutic tar-
gets for early colorectal cancer treatment. The alteration in
protein expression levels in cancer patients revealed that signif-
icant changes in glycolytic pathway, and decreased gluconeo-
genesis, glucuronic acid pathway, eventually reduced
tricarboxylic acid cycle process. Moreover, the increasing pH
range between 4 and 7 has been found and the over expression
of some metabolic enzymes such as succinate dehydrogenase
subunit A, succinyl-CoA 3-ketoacid coenzyme A transferase
and aldehyde dehydrogenase was down-regulated even though
several other proteins such as triosephosphate isomerase and
keratins 8 were up-regulated in colon cancer (Sastre et al.,
2011; Di Nicolantonio et al., 2008; Mao et al., 2011;
Coppede` et al., 2014).
1.4.1. Enzymes
The biological markers such as enzymes are very strong tools
for monitoring the progression of cell functions. It effectively
shows a new therapeutic way to control chronic diseases
including cancers. Telomerase is RNA-containing enzymes
that involve transcriptional process to synthesize DNA and
genome integrity (Roig et al., 2009). Mathioudaki1 et al.,
2008 studied/found that some telomerase was involved in the
colonic crypt activity and progressively increases the gastroin-
testinal tract function. Thus, increasing the telomerase activity
may risk treated patients who are likely to have cancer recur-
rence and may give an indication for postoperative chemother-
apy or future telomerase-targeting therapy. Antioxidant
enzymes such as superoxide dismutase (SOD), catalase
(CAT), glutathione reductase (GRx), arginine methyltransfer-Please cite this article in press as: Kuppusamy, P. et al., Proteins are potent biomarker
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plasma biomarkers that could ﬁnd prognostic of CRC risk
(Maffei et al., 2011).
1.4.2. MiRNAs
MicroRNAs (miRNAs) are very small elements of less than 22
nucleotide sequences of genome, and it is smaller piece of
RNA. miRNA is involved in different cellular functions like
proliferation, differentiation, apoptosis and metabolism
(Reid et al., 2012). Even though the functional studies on miR-
NA have not yet been fully understood, since the last two dec-
ades, a rapidly increasing number of miRNA studies have
discovered different types of miRNA and their role in onco-
genesis and gene expression level of miRNA as antioncogene.
Moreover, it is predicted that approximately 30% of protein-
encoding genes are controlled by miRNAs (Liu et al., 2011).
miRNA is a widely used biomarker for CRC detection. Clini-
cally identiﬁed different circulating miRNAs were altered in
colon cancer patients. Circulating MiRNA-92 levels were sig-
niﬁcantly higher in CRC patients than in healthy controls
and miRNA-141 was signiﬁcantly associated with stage IV
colon cancer. miRNA is used to evaluate the sensitivity and
speciﬁcity of unknown clinical samples (Allegra et al., 2012).
The prominent miRNAs such as miRNA-21 and miRNA-
31 have up-regulation in colon cancer patients and also
increase the progression of other human cancers (Markou
et al., 2008). Subsequently, Overexpression of miR-34a
strongly inhibited colon cancer cell migration and invasion.
Also, the miRNA-34a was down-regulated by more than
60% in colon cancer as compared to the adjacent normal colon
samples (Wu et al., 2012; Yang et al., 2014). MiR-31 was one
of the ﬁrst miRNAs to be found deregulated in colorectal can-
cer (Bandres et al., 2006). Other miRNA serum levels such as
miR-92a, miR-141, miR-601 and miR760 have also shown to
predict colon cancer progression and help in diagnosis
(Cortez et al., 2011; Mitchell et al., 2008). On the other hand,
miRNA is validated as a powerful cancer biomarkers for the
detection of tumor location and different subtypes of colorec-
tal cancer such as MIN (microsatellite instability), CIN (chro-
mosomal instability), and CIMP (CpG island methylator
phenotype) (Wang et al., 2012; Locker et al., 2006).
1.4.3. Cytokines
Malignant tumor has the ability to remodel the structure and
create a permissive microenvironment for their growth and
development. Consecutively, tumor cells produce soluble fac-
tors such as cytokines, growth factors and proteases. These
regulatory factors induce the growth, differentiation and sur-
vival of tumor cell progression and promotion (Klampfer
et al., 2011). Colon cancer cells induce the macrophage func-
tions to release IL-1b. The IL-1b induced NF-jB activation
is coupled to the inactivation of GSK3b function and stimula-
tion of Wnt signaling in colon cancer cells. The human colon
cancers are inﬁltrated by inﬂammatory cells including mast
cells and macrophages, which secrete TNFa. TNFa is
increased in tumor bearing mice and signiﬁcantly mast cells
were depleted in the animal model. The reduced levels of
TNFa, conﬁrmed that mast cells are important sources of
TNFa. Predominantly, the depletion of mast cells or anti-
TNFa treatment signiﬁcantly suppressed polys in colon cancer
induced mice model (Kaler et al., 2009). Kemik et al. (2010)s to detect colon cancer progression. Saudi Journal of Biological Sciences (2014),
Table 1 Summary of identiﬁed protein biomarkers from colon cancers.
No Type of cancer Clinical samples Techniques used Identiﬁed Proteins References
1 Colon cancer Serum SELDI-TOF-MS, LC–MS /MS, ELISA Transferrin, a-1 antitrypsin, apolipo
protein 1, complement c3a
Ward et al. (2006)
2 Colorectal cancer Serum SELDI-TOF-MS Two unknown proteins Zhen et al. (2006)
3 Colon cancer Serum PCR, blotting techniques Caveolin-1, Kallikrein 6 Henkhaus et al. (2008)
4 Colon cancer Serum 2DE, RT-PCR, ESI-T-MS, Immunoblotting Glucose regulated protein- 8 Xing et al., 2006
5 Colon cancer Plasma and tissue extract SELDI-TOF-MS, size exclusion chromatography a defensing -1,-2,-3 Albrethsen et al. (2005)
6 Colorectal cancer Serum SELDI-TOF-MS, MALDI-TOF-MS, LC–MS /MS, HP 3.9 KDa protein Zhai et al. (2012)
7 Colon tumor Extra cellular ﬂuid ELISA, TENDEM-MS - Fijneman et al., 2012
8 Colorectal cancer Blood serum Immunometric assay Serum C-peptide Kaaks et al., 2000
9 Colorectal cancer Serum SELDI-TOF Three diﬀerent unknown proteins Liu et al. (2010)
10 Colon cancer Serum ClinProt proﬁling technology, LTQ orbitrap XL Alpha -2- HS glycol protein Fan et al. (2014)
11 Colon cancer Serum LC–MS and MS/MS Tryptic KRT 8 peptide Zhou et al. (2009)
12 Colorectal cancer Blood plasma Lectin glycoarray/lectin blot, Nano LC–MS /MS Plasma glycol protein Qiu et al. (2008)
13 Colorectal cancer Serum MALDI-TOF-MS, Magnetic bead separation Low mass peptides Deng et al. (2013)
14 Colon cancer (CT-29) Serum LC-MRM/MS, western blot Catenin Rangiah et al. (2009)
15 Colon cancer Serum 2D- PAGE, Western blotting, RT-PCR Defensin a 6 Nam et al. (2005)
16 Colorectal cancer Serum 2D- PAGE, Western blotting, RT-PCR MMPs Zucker and Vacirca (2004)
17 Colorectal cancer Serum 2D- PAGE, Western blotting, RT-PCR Cyclin D Arber et al. (1996)
18 Colon cancer (DLD-1) Serum RT-PCR, Western blot S100 P Jiang et al., 2011
19 Colon cancer (HT-29) Serum RT-PCR, FACS, 1D-SDS PAGE Lamin A/C ﬁlament protein Willis et al. (2008)
20 Colorectal cancer Tissues 2-DE, LC-tandem MS Heat shock protein, aldehyde dehydrogenase Dwyer et al. (2011)
21 Colon cancer Serum, tissue Western blotting, RT-PCR, Immunohistochemical assay Txl-2, (thioredoxin like protein-2) Lu et al. (2013)
22 Colorectal cancer Colon tissues Immunohistochemistry P53, nm23, u-PA, VEGF Berney et al. (1999)
23 Colon cancer Colon tissues Western blot, RT-PCR Eph B4 Stephenson et al. (2001)
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6 P. Kuppusamy et al.studied that the serum IL-6 increased levels was noticed in the
metastatic-stage of colon cancer patients than without metas-
tasis patients. Also, IL-17 stimulates the tumor cell functions
to secrete a variety of angiogenic factors, including VEGF,
PGE1, PGE2, keratinocyte-derived chemokine (KC), and
macrophage inﬂammatory protein-2 (MIP-2), which promote
angiogenesis in cancer (Wu et al., 2013).
1.4.4. Chemokines
Chemokines are a large subfamily which is classiﬁed into 4 dif-
ferent groups mainly C, CC, CXC and CX3. The CC chemo-
kines are effectively functioning on various cell types,
including monocytes and lymphocytes whereas, the CXC che-
mokines merely act on neutrophils and T-lymphocytes. Che-
mokines have been ﬁrst discovered from man and it effects
by binding to 7-transmembrane domain G protein-coupled
receptors (Kulbe et al., 2004). Chemokine 25 (CCL25) and
its associated receptor chemokine receptor 9 (CCR9) inhibit
colorectal cancer (CRC) invasion and metastasis. Also,
CCR9 protein expression levels were the highest in colon ade-
nomas and gradually decreased in invasive and metastatic
CRCs (Chen et al., 2012). CCL4 has a direct effect on the
tumors and CCL5 has been the only CK found to be more
abundant in normal mucosa than in colon carcinoma tissue.
It seems that these CKs contribute more to tumor growth
rather than antitumor immunity (Baier et al., 2005).
1.5. Stem-cell associated markers
Recently, cancer stem cell (CSC) has emerged as a tool to eval-
uate the status of several solid tumors including CRC. Cancer
stem cell theory was originally proposed by Cohnheim in 1875.
This theory mainly consists of different criteria: (1) A number
of external or internal factors such as physical and chemical
agents causing genetic damages in the stem cells, (2). The dam-
aged stem cell gives a morphologically distinct type of tumor,
(3) Different tumors from different stem cells have different
biochemical and genomic proﬁles. However, CRCSC markers
might be used as a novel and effective biomarker to predict
cancer progression, and identify patients at risk for relapse
(O’Brien et al., 2007; Ricci-Vitiani et al., 2007; Papailiou
et al., 2011; Vaiopoulos et al., 2012; Rossell et al., 2013). Even
though the CSC therapy raises many questions about diagnos-
tic and therapeutic approaches for cancer and retro viral dis-
eases, CSC will be used for more efﬁcacious screening and
early detection for cancer treatment in near future.2. Techniques to predict the protein expression
2.1. Gel electrophoresis
2.1.1. 2D PAGE (2-dimentional electrophoresis)
2-D electrophoresis was ﬁrst introduced by O’Farrell and
Klose in 1975. It is commonly used to analyze proteins within
the mass range of 20–250 kDa and pH of 3–11. Gel electropho-
resis techniques have been widely used to identify the protein
expression in clinical samples. SDS, 1D and 2D PAGE tech-
niques are speciﬁcally used for the separation of complexPlease cite this article in press as: Kuppusamy, P. et al., Proteins are potent biomarker
http://dx.doi.org/10.1016/j.sjbs.2014.09.017proteins from the mixture, based on the molecular weight
(Magdeldin et al., 2014). Nevertheless, it can identify molecu-
lar weight of less than 20,000 kDa of proteins. The advantage
of 2DE is that it can detect peptide fragments with post trans-
lational modiﬁcation and amino acid mutation. Even though
2D-electrophoresis techniques have some drawbacks, it can
mainly detect only protein expression and cannot detect pro-
tein–protein interactions or protein function (Lilly et al.,
2002). For the discovery of those protein speciﬁc functions
additionally, we should use afﬁnity electrophoresis and other
functional techniques. Also, membrane proteins are difﬁcult
to separate in 2DE due to poor solubility. But this problem
can be solved by using higher protein concentrations and by
applying fractionation methods. Additionally, sometimes 2D-
electrophoresis has insufﬁcient resolution to detect the pro-
teins. The following ﬂow chart can clearly show the protein
analysis (Friedman et al., 2004).
Extraction of crude proteins from clinical samples
ﬂ
Separation of protein by SDS-PAGE based on the molecular
weight
ﬂ
Detection of protein spot and cut out from the gel
ﬂ
Gel protein was digested by protease enzymes
ﬂ
Identiﬁcation of secretory proteins by diﬀerent analytical
techniques such as Mass spectrometry, MALDI-TOF, SELDI-TOF
and protein database search tools2.2. Analytical proteomic tools
2.2.1. LC–MS (liquid chromatography–mass spectrometry)
Liquid chromatography (LC) is a separation technique widely
used in the ﬁeld of proteomic studies and life sciences. LC–MS
is commonly used for drug development at different stages
including peptide mapping, glycoprotein mapping, natural
products and metabolites identiﬁcation and quality control
(Bronsema et al., 2013). LC has emerged as a novel technique
to quantifying peptides and proteins in biological samples and
MS/MS fragmentation for each peptide sequence. Peptides
consist of amino acid residues with molecular weight
6000 Da or smaller. Peptides comprise of approximately ﬁfty
or fewer amino acid molecules (Zhou et al., 2009). Peptides
and cell adhesion proteins are signiﬁcant functions in thera-
peutics and disease development. LC–MS analytical method
is used to predict the proteins in clinical and non-clinical sam-
ples. LC–MS required a minimal quantity of sample, capable
of measuring structurally or chemically similar proteins and
peptides. The method has no requirement for antibodies to
detect the proteins. LC–MS has good accuracy and high
throughput. Additionally, some problems might occur when
using LC–MS methods for protein and peptide characteriza-
tion including poor solubility of protein in corresponding sol-
vents, chromatographic behavior, nonspeciﬁc adsorption
behavior and m/z of ionized molecules may exceed the instru-
ment’s proﬁciencies (Ewles et al., 2010).s to detect colon cancer progression. Saudi Journal of Biological Sciences (2014),
Protein biomarker as a tool for colon cancer detection 72.2.2. SELDI-TOF-MS (surface-enhanced laser desorption/
ionization-mass spectrometry)
SELDI-TOF-MS technology was ﬁrst introduced by Hutchens
and Yip in 1993. The instrumentation consists of different ana-
lytical parts mainly selective protein extraction and retention
on chromatographic chip surfaces and their subsequent analy-
sis by a simple laser desorption ionization mass spectrometer.
SELDI-TOF-MS analytical techniques can provide a rapid
protein expression proﬁle from a range of biological and clin-
ical samples (Zou et al., 2011). SELDI-TOF-MS is an estab-
lished proteomic platform which is a characterization of
signal mediating proteins from various clinical and pharmaco-
logical samples. The mass spectra data are used to identify the
molecular weight of the proteins and peptides (Emanuele et al.,
2012). Protein mass spectra from cancerous models and
healthy controls are compared and analyzed for protein
expression, which revealed novel expression of proteins in
the samples (Zhai et al., 2012).
2.2.3. MALDI TOF-MS (matrix assisted laser desorption
ionization-mass spectrometry)
Kamp, Karas and their colleagues have discovered a novel
technique matrix-assisted laser desorption ionization
(MALDI) in 1985. In 1987, Koichi Tanaka has modiﬁed the
technique which added laser desorption ionization when he
was working in Shimadzu Corp. MALDI/TOF spectra are
mainly used for the identiﬁcation of peptide ﬁngerprinting. It
may also identify the bacteria and fungi from different clinical
samples. Mass spectrometry (MS) is a technique that identiﬁes
the metabolites by separating ions by their unique mass (mass-
to-charge ratios) using a mass spectrometer (Carbonnelle et al.,
2011; Wilson et al., 2012). MALDI-TOF is a technique to ana-
lyze proteins via gas ion production and detection based on
their mass-to-charge ratio (m/z) (Deng et al., 2013). Identiﬁca-
tion of secretory proteins using a mass spectrometer is con-
nected with ion source (e.g. matrix-assisted laser desorption/
ionization (MALDI) and electrospray ionization (ESI)), a
mass analyzer and an ion detector. In the past ten years, the
proteomic techniques are very fast growing that developed
accuracy, higher sensitivity and resolution of instruments.
The cell adhesion protein and peptide fragments have been
identiﬁed by MALDI-TOF although, it is time consuming
operating process, lacks automation and requires expertise to
work in the instrumentation (Person et al., 2006; Karpova
et al., 2010). It has some disadvantages though, for instance,
it doesn’t work well if two proteins are in very close proximity
or the overlap of their relative bands and it cannot ﬁnd the
post translational modiﬁed proteins.3. Factors upset the outcome of biomarkers
Different analytical variables such as sampling methods, stor-
age, time of sample collection, sample processing, patient con-
ditions especially fasting vs non-fasting states, medications and
hormones can potentially affect biomarker concentrations.
The stability of markers is mainly focused by immediate anal-
ysis following overnight storage at carefully 4 C or 80 C. In
addition, the number of patient selection criteria for controls
and experimental should balance the cohorts (e.g. age, gender)
(Polanski and Anderson, 2006; Luo et al., 2011; Fung et al.,Please cite this article in press as: Kuppusamy, P. et al., Proteins are potent biomarker
http://dx.doi.org/10.1016/j.sjbs.2014.09.0172014). These measures are important for exploring novel pro-
tein biomarker from cancer patients. Thus, this review mani-
fests different secretory protein biomarkers used in colon
cancer prediction and we addressed a few proteomic methods
to characterize protein expression. However, this information
has been extensively applied for further protein biomarker
development and cancer drug discovery.
4. Future prospective of protein biomarkers in colon cancer
Identiﬁcation of molecular marker particularly receptor/secre-
tory proteins could improve the direction of treatment strate-
gies in colon cancer. The biomarker development may lead
to target therapies for cancers and improve the selection of
adjuvants for drug development. The use of protein biomark-
ers might also decrease the economic burden in cancer treat-
ment. Moreover, an automated and inexpensive standardized
protein marker is necessary for the detection of colon cancer.
Unfortunately, most of colon cancer cases are diagnosed at
ﬁnal stages. Therefore, by frequent evaluation of serum bio-
marker, changes can be found easily in the colon cancer devel-
opment at early stages. Cell adhesion proteins/receptors are
one of the novel biomarkers for ﬁnding colon cancer metasta-
ses in cancer biology. Also, the improvement is needed in the
current colon cancer biomarker screening assays with high
accuracy. More speciﬁc serum and tissue proteins are required
to be explored in the colorectal cancer patients and it may
enhance the new drug development. In this study, we conclude
that serum and tissue proteins should be followed-up with
colon cancer diagnosis and therefore can signiﬁcantly control
colon cancer progression. Also, the current biomarker research
is needed to search for some unique molecular identities which
could distinguish malignant tumor from normal cells.
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